Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
In a review of 87 patients, the authors recorded the clinical and histological characteristics of patients with nail psoriasis.
Read Full NewsAt CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.
New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.
Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.
In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.
A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.
Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients
1.
An "exploding" field of antibody-drug conjugates is making progress against ovarian cancer.
2.
Prostate cancer screening program beneficial in top decile of polygenic risk score
3.
Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus
4.
"We Caught It Early": Advantage or Disadvantage?
5.
New imaging technique identifies glioblastoma patients who would benefit from immunotherapy
1.
Beyond Symptoms: The Predictive Promise of Targeted Radionuclide Therapy in Palliative Oncology
2.
Understanding Apoplexy: Symptoms, Causes, and Treatment Options
3.
AI in Genomics: Decoding the Human Genome for Cancer Treatment
4.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
5.
ADCs and Bispecific Antibodies: Advancing the Future of Cancer Immunotherapy
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Navigating the Complexities of Ph Negative ALL - Part I
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
5.
Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge